Clinical trial · Interventional
Use of [18]F-FDG on PET/CT as an Alternative Non-invasive Method for Staging of Lung Cancer
Use of [18]F-FDG - PET/CT in Brazil Unified Health System (SUS) as an Alternative Non-invasive Method for Staging of Lung Cancer
NCT02664792CI-TRIAL-00026121completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the diagnostic accuracy of the 18Fluor-fluorodeoxyglucose (\[18F\]FDG) in the Positron Emission Tomography/Computed Tomography (PET/CT) as compared to mediastinoscopy for staging of non-small cel lung carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Carcinoma | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnosis or suspicion of non-small cell lung carcinoma
- description
- SUS patients with diagnosis or suspicion of non-small cell lung carcinoma with an indication for mediastinoscopy
- interventionNames
- Other: Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma
Primary outcomes (1)
- measure
- Validate the [18F]FDG as an alternative method for non-small lung carcinoma diagnosis
- timeFrame
- 4 years
Secondary outcomes (4)
- measure
- Number of patients diagnosed in a positive manner with the gold standard and with the alternative method
- timeFrame
- up to 30 days following recruitment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Individuals with histological diagnosis or high suspicion of non-small cell lung carcinoma 2. Patients who previously underwent staging of the disease with CT 3. Clinical stages I-III AJCC 7th edition. 4. Patients with indication for mediastinoscopy and linfonodal biopsy 5. Patients without treatment for lung cancer 6. Patients with biochemical and haematological exams 7. Women of childbearing potential using contraceptive methods and negative pregnancy test 8. Adults with more than 18 years old. 9. Both genders Exclusion Criteria: * Pregnant women * Patients with other types of patients
References
Publications (20)
- BACKGROUNDAlberg AJ, Ford JG, Samet JM; American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):29S-55S. doi: 10.1378/chest.07-1347. PMID 17873159
- BACKGROUNDAlberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003 Jan;123(1 Suppl):21S-49S. doi: 10.1378/chest.123.1_suppl.21s. PMID 12527563
- BACKGROUNDMolina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May;83(5):584-94. doi: 10.4065/83.5.584. PMID 18452692
- BACKGROUNDNana-Sinkam SP, Powell CA. Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e30S-e39S. doi: 10.1378/chest.12-2346. PMID 23649444
- BACKGROUNDDaigo Y, Takano A, Teramoto K, Chung S, Nakamura Y. A systematic approach to the development of novel therapeutics for lung cancer using genomic analyses. Clin Pharmacol Ther. 2013 Aug;94(2):218-23. doi: 10.1038/clpt.2013.90. Epub 2013 May 8. PMID 23657161
- BACKGROUNDSommer G, Wiese M, Winter L, Lenz C, Klarhofer M, Forrer F, Lardinois D, Bremerich J. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography. Eur Radiol. 2012 Dec;22(12):2859-67. doi: 10.1007/s00330-012-2542-y. Epub 2012 Jul 9. PMID 22772365
- BACKGROUNDMiller PW, Long NJ, Vilar R, Gee AD. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew Chem Int Ed Engl. 2008;47(47):8998-9033. doi: 10.1002/anie.200800222.